Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Ignacio Ivan Wistuba Oyarzun

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3365-6340; OpenAlex author ID A5028085268; NIH RePORTER profile ID 8625310. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
1
Labs led
1
Collaborators
57
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 1 paper, 1 grant · 2022: none · 2023: none · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 11

  1. Syndecan-1-targeted therapeutic antibody impairs macropinocytosis and elicits antitumor immunity in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2026.102613↗
  2. TREM2 Depletion in Pancreatic Cancer Elicits Pathogenic Inflammation and Accelerates Tumor Progression via Enriching IL-1β+ Macrophages. Co-author DOI 10.1053/j.gastro.2025.01.244↗
  3. Loss of p53 and SMAD4 induces adenosquamous subtype pancreatic cancer in the absence of an oncogenic KRAS mutation. Co-author DOI 10.1016/j.xcrm.2024.101711↗
  4. Genetic Deletion of Galectin-3 Inhibits Pancreatic Cancer Progression and Enhances the Efficacy of Immunotherapy. Co-author DOI 10.1053/j.gastro.2024.03.007↗
  5. Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival. Co-author DOI 10.1016/j.pan.2021.03.018↗
  6. Expression of Epithelial-Mesenchymal Transition Markers in Treated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001432↗
  7. Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients. Co-author DOI 10.1093/annonc/mdx542↗
  8. Dynamic changes during the treatment of pancreatic cancer. Co-author DOI 10.18632/oncotarget.24483↗
  9. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Co-author DOI 10.1093/annonc/mdx004↗
  10. Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy. Co-author DOI 10.1097/mpa.0000000000000914↗
  11. RSPO2 Enhances Canonical Wnt Signaling to Confer Stemness-Associated Traits to Susceptible Pancreatic Cancer Cells. Co-author DOI 10.1158/0008-5472.can-14-1327↗

Grants 1

  1. Pancreatic Ductal Adenocarcinoma Translational Resource Center (PATReC) U24CA224020↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anirban Maitra · 9 shared papers, 1 shared grant, 2017–2025 · strength 1.57
  2. Daowei Yang · 3 shared papers, 2024–2025 · strength 0.70
  3. Yang Chen · 3 shared papers, 2024–2025 · strength 0.70
  4. Xinlei Sun · 3 shared papers, 2024–2025 · strength 0.70
  5. Huamin Wang · 5 shared papers, 2017–2024 · strength 0.68
  6. Subrata Sen · 1 shared grant, 2021 · strength 0.44
  7. Matthew H. G. Katz · 6 shared papers, 2017–2021 · strength 0.43
  8. Hua Wang · 3 shared papers, 2017–2024 · strength 0.38
  9. Robert A. Wolff · 5 shared papers, 2017–2021 · strength 0.38
  10. Gauri Rajani Varadhachary · 5 shared papers, 2017–2019 · strength 0.31
  11. Jeffrey E. Lee · 3 shared papers, 2017–2021 · strength 0.26
  12. Zecheng Yang · 1 shared paper, 2026 · strength 0.22
  13. Yongkun Wei · 1 shared paper, 2026 · strength 0.22
  14. Timothy Paul Heffernan · 1 shared paper, 2026 · strength 0.22
  15. Haoqiang Ying · 1 shared paper, 2026 · strength 0.22
  16. Wantong Yao · 1 shared paper, 2026 · strength 0.22
  17. Giulio Francesco Draetta · 1 shared paper, 2026 · strength 0.22
  18. Hua Wang · 1 shared paper, 2024 · strength 0.21
  19. Michael P. Kim · 2 shared papers, 2019–2021 · strength 0.21
  20. Kelvin Allenson · 3 shared papers, 2017–2018 · strength 0.17
  21. Vincent Bernard · 3 shared papers, 2017–2018 · strength 0.17
  22. Hector A. Alvarez · 3 shared papers, 2017–2018 · strength 0.17
  23. Jun Zhao · 1 shared paper, 2021 · strength 0.12
  24. Laura R. Prakash · 1 shared paper, 2021 · strength 0.12
  25. Ching-Wei David Tzeng · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.